Novartis’ lymphoma treatment receives FDA breakthrough therapy designation
19 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is…